STAGE IV LUNG CANCER AJCC V8

This early-phase study tests a combination of all-trans retinoic acid (a vitamin A derivative) and the immunotherapy drug atezolizumab in adults with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand side effe…

This study looks at whether using focused radiation (stereotactic radiosurgery) only on the brain tumors, instead of the whole brain, can help preserve thinking and memory in people with small cell lung cancer that has spread to the brain. About 55 participants will receive this …

This study tested two drugs—osimertinib and bevacizumab—in people with a specific type of lung cancer (EGFR mutation-positive) that had spread to the brain. The goal was to see if adding bevacizumab to osimertinib could help control the cancer longer. Only 5 patients took part, a…

This early-phase trial tested the safety of combining two drugs, nivolumab and cabozantinib, in 8 people with HIV who also have advanced solid tumors. The goal was to see if the combination is safe and can shrink or stabilize the cancer. The study focused on finding the right dos…

This early-phase trial tests the safety and best dose of a new drug (BAY 1895344) when given with standard chemotherapy (irinotecan or topotecan) for people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic …

This early-phase study tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in adults with advanced solid tumors that have spread or can't be removed. The main goal is to find the safest dose and check for side effects. About 66 people with cancers like col…

This phase 3 study tests whether starting with immunotherapy alone (pembrolizumab) and adding chemotherapy only if the cancer worsens is better than starting with both immunotherapy and chemotherapy together for advanced non-squamous lung cancer. About 600 patients with stage IV …

This early trial tests combining the targeted drug brigatinib with local treatments like surgery or radiation for people with advanced ALK-positive non-small cell lung cancer. The goal is to see if this approach is safe and helps control the cancer longer. About 35 participants w…

This study tests a combination of three drugs (niraparib, temozolomide, and atezolizumab) in people with advanced solid tumors or extensive-stage small cell lung cancer that has responded to initial chemotherapy. The goal is to find the safest dose and see if the combination help…

This study tests a combination of the CIMAvax vaccine and nivolumab (an immunotherapy drug) in people with advanced non-small cell lung cancer or squamous head and neck cancer. The goal is to find the best dose and see if the combination helps control tumor growth and improve sur…

This study tests whether a lung cancer drug called atezolizumab can be safely given as a shot under the skin at home, with doctors monitoring patients through video calls. It involves 5 adults with non-small cell lung cancer. The goal is to see if this home-based approach is prac…

This study looks at whether adding surgery or radiation to the targeted drug osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 173 participants will receive either osimertinib alone or osimertinib plus lo…

This study compares two treatments for lung tumors: microwave ablation (using heat to kill cancer cells) and surgical wedge resection (removing a small piece of lung). It includes adults with non-small cell lung cancer, sarcoma, or colorectal cancer that has spread to the lungs. …

This study tests whether a combination of two drugs (ramucirumab and pembrolizumab) works better than standard chemotherapy for people with advanced or returning non-small cell lung cancer who have already tried immunotherapy. About 838 participants will be randomly assigned to o…

This early-stage trial tests a new drug (BAY 1895344) combined with standard chemotherapy for people with advanced solid tumors, especially bladder cancer. The goal is to find the safest dose and see how well the combination works. About 74 adults with cancers like lung, ovarian,…

This study tests whether adding local treatments like surgery or radiation to immunotherapy (nivolumab and ipilimumab) helps people with stage IV non-small cell lung cancer live longer. About 339 participants will receive immunotherapy alone or with local therapy. The goal is to …

This early-phase trial tests the safety and best dose of sonidegib combined with pembrolizumab in 36 adults with advanced solid tumors (cancers that have spread). Sonidegib blocks enzymes that help tumors grow, while pembrolizumab boosts the immune system to attack cancer. The go…

This study tests a mix of drugs (olaparib, durvalumab, carboplatin, etoposide) plus radiation in people with advanced small cell lung cancer that has spread. The goal is to see if this combination is safe and works better than standard treatment. About 63 participants will take p…

This early-phase trial tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment uses immune cells from donated umbilical cord blood that are genetically modified to better recognize and attack cance…

This early-phase study tests a new drug combination for people with advanced ALK-positive non-small cell lung cancer. The goal is to find the best dose of ensartinib when given with standard chemotherapy and a targeted antibody. About 12 participants will receive the treatment to…

This study tests two drugs together—trametinib and pembrolizumab—in people with advanced non-small cell lung cancer that has returned or spread. The goal is to see if the combination can shrink tumors or slow the cancer's growth. About 37 participants will receive the treatment, …

This early-phase trial tests the safety and best dose of a new drug called minnelide when combined with the standard drug osimertinib for people with advanced EGFR-mutant non-small cell lung cancer. Only 8 participants are enrolled. The goal is to find side effects and the right …

This study tests the safety and best dose of adding telaglenastat to the standard drug osimertinib for people with stage IV non-small cell lung cancer that has a specific EGFR mutation. The two drugs work together to block enzymes that cancer cells need to grow. The trial involve…

This early-phase trial tests a drug called WSD0922-FU in 56 people with certain brain cancers (glioblastoma, anaplastic astrocytoma) or lung cancer that has spread to the brain or spine. The drug blocks a protein called EGFR, which helps some cancers grow. The main goals are to f…

This study tests a new combination of drugs for people with advanced squamous non-small cell lung cancer that has spread. The treatment includes a targeted drug (berzosertib), chemotherapy (carboplatin and gemcitabine), and an immunotherapy (pembrolizumab). The goal is to find th…

This study tests a drug called selpercatinib in people with advanced or returning non-small cell lung cancer that has a specific gene change (RET fusion). The drug works by blocking signals that help cancer cells grow. About 124 participants will receive the treatment to see if i…

This study tests a combination of three drugs (chemotherapy, anti-angiogenesis, and immunotherapy) in 30 adults with advanced non-small cell lung cancer that worsened after standard treatments. The goal is to see if this triple therapy is safe and works better than current option…

This early-stage trial tests a drug called berzosertib combined with whole brain radiation for people with lung cancer that has spread to the brain. The main goal is to find the safest dose and check side effects. About 15 adults with non-small cell, small cell, or neuroendocrine…

This early-phase trial tests two experimental drugs, sapanisertib and telaglenastat, in people with advanced non-small cell lung cancer that has spread or come back after standard treatments. The main goals are to find the safest dose and see if the combination can shrink tumors …

This early-phase study tests a combination of two drugs, brigatinib and bevacizumab, in people with a specific type of lung cancer (ALK-positive) that has spread or returned after prior ALK-directed therapy. The main goals are to find the best dose and check for side effects. Onl…

This study tests a combination of two drugs, atezolizumab and cobimetinib, in people with advanced non-small cell lung cancer that has spread, returned, or stopped responding to standard immunotherapy. The goal is to see if this combo can shrink tumors for at least 6 months. Abou…

This study tests a new drug combination for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). The two drugs, LY3295668 and osimertinib, work by blocking enzymes that help cancer cells grow. The goal is to find the safest dose and see if…

This early-phase trial studies the safety and best dose of adding necitumumab to osimertinib for people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous treatment. About 138 participants will receive the combination to see if it is tolerable a…

This study tests a DNA vaccine called STEMVAC in people with stage IV non-small cell lung cancer. The vaccine gives the body instructions to make parts of five proteins found on lung cancer cells, helping the immune system recognize and attack them. About 5 participants who have …

This study tests two new treatments—cabozantinib alone or with nivolumab—against standard chemotherapy for people with advanced non-squamous lung cancer that has returned. The goal is to see if these combinations can slow cancer growth better than current options. About 117 adult…

This phase 2 study tests a new drug (pevonedistat) combined with two standard chemotherapies (carboplatin and paclitaxel) in 27 adults with advanced non-small cell lung cancer that has not responded to immunotherapy. The goal is to see if this combination can shrink or control th…

This study looks at whether adding radiation therapy to standard immunotherapy (with or without chemo) helps people with advanced non-small cell lung cancer that lacks the PD-L1 marker. About 427 adults with stage IIIB, IIIC, or IV cancer will be randomly assigned to get either t…

This study tests whether adding N-803 (a natural killer cell booster) to pembrolizumab (an immunotherapy) can help shrink or stabilize advanced non-small cell lung cancer in patients whose previous immunotherapy stopped working. About 82 participants will receive either the combo…

This study tests a drug called AMG 510 in people with advanced lung cancer that has a specific genetic change (KRAS G12C mutation). The drug is designed to block the cancer's growth signal. About 116 participants will receive the treatment to see if it can shrink tumors and slow …

This study looks at whether a drug called anamorelin can help improve appetite and prevent weight loss in people with advanced non-small cell lung cancer who have lost their appetite and are losing weight. About 25 participants will take either the drug or a placebo and share the…

This study tests an online program designed to help women with lung cancer feel more supported and less distressed during treatment. The program uses techniques like mindfulness and emotional processing to improve social well-being. About 70 women with stage I-IV non-small cell l…

This study looks at whether updating radiation treatment plans at set times (adaptive planning) can lower side effects like lung inflammation in people with stage II-IV non-small cell lung cancer. About 34 participants will receive standard radiation and immunotherapy, but their …

This study tests a nurse-led program designed to help people with advanced lung or gynecologic cancer cope with fears about their future. About 42 participants will try the program, which includes sessions and home activities. The goal is to see if the program is practical and he…

This early-stage study tests whether giving a single, very focused dose of radiation after lung cancer surgery is safe and causes fewer side effects than standard weeks-long radiation. It involves 50 adults with non-small cell lung cancer who had surgery but still have cancer cel…

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. Researchers will track these samples over time to learn how cancer changes and why some treatments stop working. The goal is to build a resource for futu…

This study is testing a low-literacy conversation tool designed to help people with lung cancer and their doctors make treatment decisions together. About 98 adults with non-small cell lung cancer will use the tool and report on their anxiety, decision confidence, and satisfactio…

This study tests whether watching a short video helps people with metastatic cancer understand what tumor genomic testing is and why it matters. About 243 adults with advanced cancer will watch the video and answer questions before and after. The goal is to see if the video impro…

This study looks at whether doctors can consistently measure the chemotherapy drug paclitaxel in the blood of cancer patients. The goal is to see if adjusting the dose based on these levels could reduce nerve damage, a common and severe side effect. About 22 adults with various s…